EP Patent

EP2581381A2 — Process for preparing an A2A-adenosine receptor agonist and its polymorphs

Assigned to Gilead Sciences Inc · Expires 2013-04-17 · 13y expired

What this patent protects

Disclosed is a synthesis suitable for large scale manufacture of an A2A- adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.

USPTO Abstract

Disclosed is a synthesis suitable for large scale manufacture of an A2A- adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.

Drugs covered by this patent

Patent Metadata

Patent number
EP2581381A2
Jurisdiction
EP
Classification
—
Expires
2013-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.